1 Article

2

4

6

- Assessment of Attitude and Hesitancy Towards Covid-19 Vaccine among
- 3 Hepatitis B and C Patients in Pakistan
- 5 Short Title: Refusal to covid-19 vaccine among viral Hepatitis patients in Pakistan
- 7 Farheen Shafiq¹,
- 8 https://orcid.org/0000-0003-3658-9729
- 9 Mahreen ul Hassan²*
- 10 https://orcid.org/0000-0002-5524-9765
- 11 Sadia Butt³
- 12 https://orcid.org/0000-0002-3631-3354
- 13 Sadia sidique⁴
- 14 https://orcid.org/0000-0001-6483-3579
- 15 Nazia Akbar ⁵
- 16 <u>https://orcid.org/0000-0003-2203-4933</u>
- 17 Azra⁶

- 18 https://orcid.org/0000-0002-3088-2345
- 19 Irshad Rehman⁷
- 20 <u>https://orcid.org/0000-0002-2724-6946</u>
- 22 *Correspondence:
- 23 **Dr. Mahreen ul Hassan**
- 24 https://orcid.org/0000-0002-5524-9765
- 25 Email:microkust@sbbwu.edu.pk
- 26 Contact no.03348483041
- 27 78 Western Bank
- 28 Firth Court
- 29 Department of Bioscience
- 30 University of Sheffield, UK
- 31 S10 2TN
- 32 Sheffield, South Yorkshire
- 33 United Kingdom

ABSTRACT

34

- 35 **OBJECTIVE**: The research aimed to evaluate the attitude and perceptions towards the covid-19
- vaccine among Hepatitis B and C patients in Peshawar, Khyber Pakhtunkhwa, Muzaffarabad,
- 37 Azad Kashmir, Pakistan.
- 38 **METHODS**: A survey-based study was adopted to evaluate the attitude of Hepatitis B and C
- patients towards immunization against covid-19 in Peshawar (KPK) and Muzaffarabad (AJK)
- 40 cities of Pakistan. The study continued from January 2020 to February 2021. Participants were
- also assessed for their perception towards covid-19 vaccination.
- 42 **RESULTS:** A total of 839 (33.6%) individuals participated in the study. About 52 % of
- 43 Hepatitis B patients were immunized against Covid-19, whereas the number of Hepatitis C
- patients was recorded at around 48%. About 53.7 % of participants refused to get the vaccine
- without any reason. About 63.2% of patients showed concern about the insufficient data
- 46 available on the vaccine safety and efficacy published by the Public Health Department.
- 47 Individuals with higher education were observed to be more open towards vaccination then those
- without a formal education. More than half of the participants (61.5 %) were concerned about the
- interference of the vaccine with their hepatitis treatment whereas 54.7 % patients refused vaccine
- 50 because of a poor liver condition.
- 51 **CONCLUSIONS:** The data indicated that limited data availability regarding the vaccine
- efficacy in viral hepatitis patients and negative attitudes of people toward covid-19 vaccination is
- 53 the main cause of Covid-19 vaccination refusal among hepatitis B and C patients.
- 54 **DESCRIPTORS:** Hepatitis B, Hepatitis C, covid-19, immunization, vaccine refusal, Pakistan.

INTRODUCTION

- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the 7th human coronavirus,
- was reported in Wuhan, Hubei province, China, in January 2020¹⁻². In early 2020, the World
- 58 Health Organization (WHO) declared it a pandemic and requested the world to take strict
- 59 measures to control the disease as there was no effective treatment available, and the death toll
- was rising every hour across the world³.

- The SARS-CoV-2 is an airborne virus which can be transmitted through air therefore effective
- 62 preventive measures like social distancing, frequent handwash and wearing a mask in the
- absence of a valid treatment or vaccine to control the disease was imperative⁴.
- Patients with covid-19 may have abnormal liver function or hepatic dysregulation, which may
- 65 identify as cholestasis, hepatitis, or both. In an early study from China, increased total bilirubin
- was observed in 18 (18%) patients and higher serum alanine aminotransferase (ALT) was
- recorded in 28 (28%) of 99 individuals with covid-19⁵.
- 68 It is suggested that SARS-CoV-2 may exacerbate liver damage in individuals with chronic viral
- 69 hepatitis⁶. According to Xu et al. (2020), liver dysfunction occurs more often and more severely
- as covid-19 progresses. Liver function tests are typically normal or somewhat raised in the early
- 71 stages of SARS-CoV-2 infection. Histological examination of the liver reveals syncytial
- 72 multinuclear hepatocytes, microvascular steatosis, and little lobular and portal activity.
- 73 The cytokine storm caused by the progression of severe covid-19 cases requiring strong
- 74 immunosuppressive therapy has raised the problem of recurrence of HBV infections in the
- 75 patients with a history of HBV^8 .
- In a study conducted by Ronderos et al. (2021), patients with covid-19 having history of
- 77 hepatitis C virus (HCV) or seropositivity for HCV infection have an increased susceptibility to
- 78 SARS-CoV-2 infection, which is a strong predictor of in-hospital mortality regardless of
- 79 preexisting conditions, laboratory results upon admission, or the severity of covid-19-induced
- 80 liver injury.
- With an estimated 9.8 million chronic HCV patients, Pakistan has the second-highest burden of
- HCV infection in the world¹⁰. Unscreened blood transfusions, a history of hospitalization, dental
- work, tattooing, body piercing, the use of injections, and a history of surgery are the main risk
- factors for the transmission of HCV¹¹. According to government statistics, around 2.5% of
- Pakistan's population was infected with HBV in 2008. There was a 5% rise in HCV-related
- mortality and an 8% increase in HBV-related deaths between 2015 and 2019¹⁰.
- 87 According to World Health Organization vaccination is an easy, safe, and efficient way to avoid
- infection especially in the absence of an effective therapy as in the case of covid- 19^{12} .

89 Vaccination is the most significant medical intervention in the human history which has largely eradicated the infectious diseases that formerly claimed the lives of millions of people¹³. 90 Currently, more than 30 infectious diseases could be avoided with the use of vaccinations¹⁴. 91 According to an estimation, the immunization against covid-19 have prevented thousands of 92 93 deaths and saved millions of people from getting infection in England and United States till June 2021^{15-16} . 94 Pakistan is also badly affected by covid-19 pandemic. Currently there are 1,573,922 confirmed 95 covid-19 cases from which 2,928 are marked as active in different areas of Pakistan and about 96 30,625 causalities have been observed from 2020 to date ¹⁷. 97 98 The Chinese government sent more than 500,000 doses of the Chinese Sinopharm vaccine to Pakistan in February 2021, and the Pakistani government opted to prioritize immunizing 99 frontline healthcare workers¹⁸. Pakistan initially restricted immunization to those aged 18 and 100 older before expanding the program. The government was placing a higher priority on heavily 101 102 populated metropolitan centers and "hotspot" locations, where the coronavirus transmits more rapidly than in more distant rural communities¹⁹. It is estimated that about 69.9 % population in 103 104 Pakistan has taken at least on dose of covid-19 vaccine. The number is not very discouraging but nature of disease and its transmission along with the emergence of new Corona virus variants 105 106 every 6 month makes it crucial to get the entire population immunized in limited time to control the disease¹⁷. 107 108 Vaccine hesitancy is one of the top 10 global health problems, according to the World Health Organization²⁰. Fear of the covid-19 vaccination is a growing problem that Pakistan is also 109 dealing with. It is one of the nations with lowest vaccination rates²¹. Myths such as the vaccine 110 causes sterility, the pandemic is a foreign conspiracy, or the virus is harmless are common 111 contributors to the hesitation towards covid-19 vaccination²². 112 113 In current study have sought to understand the current level of awareness of covid-19 transmission, symptoms, and preventive measures specifically among Hepatitis B and C patients. 114 The study also aimed to identify the risk variables that contribute to ambivalence towards covid-115

19 vaccination among hepatitis patients residing in KPK and AJK, Pakistan.

METHODOLOGY

116

Study Location and Settings

118

119

123

130

137

139

- Survey-based research was conducted in Peshawar and Muzaffarabad from January 2020 to
- February 2021. A questionnaire was prepared for the study. An epidemiologist, field surveyor,
- and health care practitioner assisted in the development of a questionnaire. To calculate the
- reliability score and Cronbach alpha, the questionnaire was pretested in a pilot study.

Sample Size and Exclusion Criteria

- For the evaluation of the knowledge and perception of the hepatitis B and C patients toward
- 125 covid-19 and the vaccination program the questionnaire was distributed throughout the
- community where these patients were easily accessible. Hepatitis B and C patients age 18 years
- and above were deemed eligible. Participants who refused to provide any information or who
- were temporary residents were barred from participating. The questionnaire was created to
- identify potential challenges to covid-19 immunization.

Designing and Validating the Questionnaire

- Following a thorough review of the relevant literature, a questionnaire was designed. It was
- composed in English, then translated into Urdu and Pushto for participants before translated back
- to English for analysis. The questionnaire was divided into two sections, each with 16 questions.
- Section one had ten questions that assessed demographic data such as age, gender, race, income,
- marital status, and so on. The next section included 16 questions designed to test participants'
- knowledge and perceptions about covid-19 and its vaccination.

Statistical Analysis

Data evaluation was performed through SPSSv21 statistical package.

Ethical Approval and Consent of Participants

- 140 This study was approved by the Research and Ethics Committee of Shaheed Benazir Bhutto
- Women University Peshawar, Pakistan. A filled and signed informed consent form was collected
- from each participant before the participation. All the information of the participants is kept
- 143 confidential.

RESULTS

144

145

155

156

157

158

159

160

161

162

163

164

165

166

Demographic Details of the Respondents

- A total of 839 responses were collected, of which 36.1% (303) were female and 63.9% (536)
- were from male respondents. Table 1 displays the demographic data (age, gender, place of
- residence, educational background, occupation, and monthly income) of the survey respondents.
- About 48% responses were collected from Hepatitis B patients whereas the response rate of
- Hepatitis C patients was 52 %. Age-wise most of the patients were young (57.1%) while it was
- observed that the number of respondents were mostly male (63.9 %) that could be due to the
- 152 cultural barriers in the area. The data generated through this study revealed the about 35.5%
- hepatitis patients were still unvaccinated due to various reasons.
- Table 1. shows demographic data frequencies of the participants. (n = 839).

Approved Vaccines in Pakistan

In Pakistan, every person above age 18 was bound to get one of the approved Covid-19 vaccines to minimize the devastating effects of pandemic according to National Action Plan for Corona virus disease (covid-19) Pakistan^a (Table S1). For the purpose, Government of Pakistan worked tirelessly making the best vaccines widely available to the public. As a result, about 10% of the population received the first by the mid of year 2021. The information presented in Table 6 was generated as a secondary data by utilizing all the reliable resources available e.g., National Institute of Health Pakistan^b, WHO^c and dedicated website for covid-19 related information by the Ministry of National Health Services Pakistan^d. Likewise, it was advised that everyone with a known underlying disease, including those with hepatitis, immunize themselves against covid-19.

Table 2- Commercially available Vaccines approved by the Government of Pakistan.

- 167 It was observed during the study that around 65 % participants were fully immunized (Figure
- 168 la), and rest of the participants refused after taking first dose to immunize due to some reasons
- 169 (Figure 1b).

^a https://www.nih.org.pk/wp-content/uploads/2020/04/COVID-19-NAP-V2-13-March-2020-1.pdf

https://www.nih.org.pk/public/novel-coranavirus-2019-ncov

c https://covid19.who.int/region/emro/country/pk

d https://covid.gov.pk/

170 Figure 1a. No. of patients receiving covid-19 vaccines from approved pharmaceuticals. b. No. of Patients refused to get immunized. 171 172 The main objective of this study was to evaluate the hepatitis patients' awareness of the covid-19 173 vaccination and the fears that were keeping them from receiving the vaccine. For the purpose a derailed interview was arranged with each participant and their answer were recorded for further 174 175 analysis. Attitude and Perceptions towards covid-19 vaccination 176 177 The questionnaire was split in two parts i.e., part A (Table 3a) where patients were assessed why they chose to get immunized against covid-19. Part B (Table 3b) was specifically designed for 178 179 the patients who refused to take covid vaccine. The questionnaire A analysis revealed that most participants (79.5%) were happy to get 180 181 vaccinated because there were no charges of that vaccine as compared to the Hepatitis C vaccine 182 available in the markets (Table 3a). Many participants (76.9%) believed that the vaccine would protect them from covid-19. About 76.5% people claimed that thy were encouraged when they 183 realized that other hepatitis patients were also getting vaccine. As a reflection of their confidence 184 in their doctors, 469 out of 710 people (71.2% of the total) vaccinated themselves after medical 185 186 professionals encouraged them to do so. Yet 374 (56.8%) patients showed concern about the 187 insufficient data available on the vaccine safety and efficacy published by the Public Health Department. 188 189 Table 3a. Assessment of patients choosing covid-19 vaccine for protection. b. Question statements to assess Hepatitis patient for refusing covid-19 vaccine. 190 There were many explanations given by individuals when asked why they didn't want to be 191 192 vaccinated (Table 3b). About 74.1 % of participants had a view that precautionary measures like 193 social distancing and wearing a mask or visor could protect them from getting coivd-19 194 infection. Some people refused (63.2 %) to get vaccination simply because they did not have enough information about the vaccine due to unavailability of literature regarding outcomes of 195 196 covid vaccination. Interestingly, half of the patients (53.7 %) were simply against any type of immunization whatever vaccine it was and perceived the immunization as a part of foreign 197 198 agenda. However, 181 (61.5 %) patients were worried that the vaccine might interact with their

hepatitis therapy as there is no published data available which can prove it wrong; people don't

believe in assumptions especially in case of a health-related issue. The study also revealed that about 54.7 % of total participants were concerned about their liver condition as they were already dealing with a liver infection. The fear of an over-burdened liver cannot be overlooked. More than half (57.5 %|) of the patients who were against the vaccination were of view that there is no point to get vaccination if it is not protecting you against the infection. Around 58.5 % participants were of view that they have immunity against the disease due to the previous covid infection. Unfortunately, some patients (12.2 %) got allergic reactions after getting first dose due to which they feared to try another type of covid vaccine.

Correlation between various parameters

- Table 4a showed positive and negative correlation between various parameters of hepatitis patients with respect to the trend towards covid-19 vaccine. A very strong relationship (.104**) was found among the self-employed people toward the covid vaccine as compared to the people related to other sources of income. The trend showed that there was a significant difference among the people of various education levels. The participants having higher levels of education were more agreed to get vaccinated against covid-19 as compared to others. Surprisingly, participants having high incomes were showed a highly significant difference and were less likely to get vaccinated (-.119**) and same was the trend seen in case of females (-0.018). All age groups showed a weak relationship between patients and their attitude towards the covid vaccine. A negative correlation was seen in case of ethnicity and location. It was revealed that participants from Punjabi origin were reluctant (-0.064) to get vaccinated as compared to Kashmiri and Pathans. The study also revealed that less people from Muzaffarabad AJK were get vaccinated (-0.022) than those from Peshawar, KPK.
- Table 4a. Correlation between different variables of Hepatitis B and C patients with the
- 223 covid-19 vaccine approval or rejection. b. Spearman correlation between different variables
- 224 and covid-19 vaccine.

Relationship between Demographic Characteristics and Responses of Participants

- Associations of different characteristics were made against the participants' knowledge of covid-
- 19 (Table 4b). First, education levels of the participants were evaluated against the use of mask
- by the participants. It was observed that the use of mask was significantly less among individuals
- 229 with lower education levels as compared to individuals with higher education (P 0.064).

However, non-significant relationships were present between education level and other aspects of our study such as attending social gatherings, frequent hand washing, and covid-19 as a bioweapon. Second, income levels of the participants were analyzed against various factors. A significant relationship was found among the income level of the participant and their affinity to join social gatherings during the covid-19 pandemic. It was observed that respondents with lower income levels were more likely to attend gatherings as compared to higher income respondents. Similarly, income level was also found to be associated with the subjects' use of mask. Participants with higher income levels were wearing N95 and surgical masks, whereas cloth masks were usually used by lower-income respondents. Terminally higher- and lower- income category subjects wore fewer masks as compared to middle-income-range groups. More participants in the lower-income category had to leave their jobs or had their business shut down during the covid-19 pandemic as compared to higher-income respondents. Likewise, more women have left their jobs as compared to their male counterparts. However, business shutdown trend mainly affected the male gender. Moreover, the males were found to wear mask more often than the females. Females usually wore N95 masks, whereas male respondents relied more on surgical masks or cloth masks. On the contrary, no significant associations were present among all the characteristics with hand-washing practices and the use of covid-19 as bioweapons.

DISCUSSION

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

In Pakistan, the combined number of persons infected with hepatitis B virus (HBV) and hepatitis C virus (HCV) is over 15 million¹². Free treatment for viral hepatitis is being offered throughout the nation thanks to the Hepatitis Prevention and Treatment Program and other government-funded initiatives²³. At a time when a worldwide effort to eliminate viral hepatitis was essential, covid-19 placed a significant burden on national healthcare systems. According to Mustafa et al.²⁴ (2021), with the rise of covid-19 cases in early 2020, a sharp decline in visits of viral hepatitis patients was observed to their respective clinics across Pakistan. However, an estimated 325 deaths because of viral hepatitis were also reported each day. The data suggested that there was a clear shift of priority towards the Covid patients due to unavailability of a valid treatment and increased number of causalities.

Current study is unique as it primarily examined how the Hepatitis B and C patients residing in

Peshawar KP and Muzaffarabad AJK have responded to the covid-19 immunization program.

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

Currently no data is available regarding concerns of hepatitis patients in the area, therefore, we have assessed the participants concerns regarding the vaccine and compared it with the other studies conducted in the world. As described in the Health Belief Mode, the preventive actions, like getting a vaccination, depend on how people see the risks of disease and how they perceive the effectiveness, benefits, and costs of these actions²⁵. Pakistan and Afghanistan are two countries where nation-wide immunization has always been challenging as we have seen in the case of polio eradication program according to Shafique et al.²⁶ (2021). In this study it was initially decided to contact maximum number of viral hepatitis patients residing in the study area. However, it was observed that most of the patients avoid such interviews due to some reasons. Therefore, we could succeed to interview around 839 patients. The survey revealed that majority of the participants (79.5%) were open to vaccination which shows appositive attitude towards the covid-vaccination. The reason might be the easy availability of the vaccine and an active covid-19 eradication program in which healthcare workers are going door to door to make sure everyone has got vaccinated. The results were even better than a similar study conducted by Tahir et al.²⁷ in 2021. However, there are still number of individuals which are not immunized due to some reason which is a real concern. It is also notable that majority of the individuals who participated in this study was between the age of 18 and (57.1 %) which indicates that young generation is more open to express their opinion about health issues. There were mixed responses when the participants were asked whether a patient suffering from viral hepatitis should get immunized. Most of the patients (54.7 %) refused to get fully vaccinated despite the government's strict orders because they were worried about their liver condition. Unfortunately, there is not much data about the effect of covid vaccines on the liver of hepatitis B and C patients specifically. Therefore, it is nearly impossible to persuade a person for getting a vaccination with a poor liver condition. Furthermore, there are some studies that have reported the postvaccination Autoimmune Hepatitis (AIH)²⁸⁻³² which makes it essential to study the health of viral hepatitis patients after vaccination to devise a better strategy for hepatitis patients in order to prevent covid-19.

More than half of the patients (57.5 %) who refused to take the 2nd dose individuals believed that covid-19 vaccination might not protect them from the covid-19 infection because they got ill or observed that people contracted infection even getting vaccinated. The concern is authentic; there are many cases reported around the world where vaccines have failed to prevent individuals from the disease. For instance, in a recent study Jain et al.³³ (2021) reported that despite its effectiveness in preventing masses from the adverse effects of covid infection the covid vaccine was not proved suitable for certain individuals and postvaccination infection even deaths have been raised many questions on the efficacy of the vaccine especially in patients with vulnerability. There were a few participants (12.2 %) who were covid against the vaccination because they developed adverse reactions after getting the 1st dose of covid vaccine. This concern was not baseless as many though rare but incidents regarding hypersensitivity reaction to covid vaccine have been reported since 2020 vaccine roll out³⁴. About 218 (74.1 %) out of total participants believed that strict Standard Operating Procedures (SOPs) could prevent them from infection. Their belief was not wrong as we have seen that strict precautionary measures have saved masses when there was no vaccine available during the pandemic back in 2020. In random studies Kissler et al.³⁵ (2020) and Moosa³⁶ (2020) analyzed that social distancing has appeared to be quite effective to contain the covid infection when there was no vaccine available. Similarly, Hsieh et al³⁷. 2020, reported that preventive measures such as social distancing, using Personal Protective Equipment (PPE), and frequent handwashing, etc. at a personal level could be significantly helpful to control the covid infection in the absence of other interventions. However, their approach to avoid covid-19 infection was not realistic. It is impossible to avoid social contact in this fast-paced life and sometimes SOPs are not enough. It is observed in various studies though minimal but there are still chances to get infected by

CONCLUSION

following SOPs only³⁸.

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

It was concluded that despite a successful covid-19 prevention program in Pakistan the concern towards the safety and efficacy of covid vaccine is still there. The study revealed that the reason to refuse vaccination cannot be neglected as they are genuine and need to be addressed carefully.

- 317 Additionally, addressing the issues regarding vaccine refusal requires genuine data
- demonstrating the benefits of vaccines in viral hepatitis patients is inevitable in order to resolve
- 319 the ambiguity related to covid vaccination efficacy.

LIMITATIONS IN STUDY

320

326

327

- Despite many efforts for making this study possible, it has a few limitations. First, the study area
- was confined to only two cities Peshawar and Muzaffarabad which is not enough to portray a
- 323 clear picture of the current situation in Pakistan. Secondly, the resistance towards covid-19
- vaccination-related reporting also makes data collection difficult. Natives especially hepatitis
- patients usually do not want to take part in such studies to avoid stigmatization.

REFERENCES

- 1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL,
- 329 Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat
- origin. nature. 2020 Mar;579(7798):270-3.
- 2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY,
- Yuan ML. A new coronavirus associated with human respiratory disease in China.
- Nature. 2020 Mar;579(7798):265-9.
- 3. World Health Organization Coronavirus Disease 2019(COVID-19) Situation Report-97.
- 335 Available from: https://www.who.int/docs/default-source/coronaviruse/situation-
- reports/20200426-sitrep-97-covid-19.pdf.
- 4. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio Medica: Atenei
- Parmensis. 2020;91(1):157.
- 5. Liao M, Liu H, Wang X, Hu X, Huang Y, Liu X, Brenan K, Mecha J, Nirmalan M, Lu
- JR. A technical review of face mask wearing in preventing respiratory COVID-19
- transmission. Current Opinion in Colloid & Interface Science. 2021 Apr 1;52:101417.
- 6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T.
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus

- pneumonia in Wuhan, China: a descriptive study. The lancet. 2020 Feb 15;395(10223):507-13.
- 7. Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, Genescà J,
- Gill US, James TW, Jones PD, Marshall A. High mortality rates for SARS-CoV-2
- infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary
- results from an international registry. Journal of hepatology. 2020 Sep 1;73(3):705-8.
- 8. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y.
- Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
- The Lancet respiratory medicine. 2020 Apr 1;8(4):420-2.
- 9. Baroiu L, Anghel L, Tatu AL, Iancu AV, Dumitru C, Le□e AC, Drăgănescu M, Năstase
- F, Nicule E, Fotea S, Nechita A. Risk of hepatitis B reactivation: From biologic
- therapies for psoriasis to immunosuppressive therapies for COVID-19. Experimental and
- Therapeutic Medicine. 2022 Jun 1;23(6):1-9.
- 10. Ronderos D, Omar AM, Abbas H, Makker J, Baiomi A, Sun H, Mantri N, Choi Y,
- Fortuzi K, Shin D, Patel H. Chronic hepatitis-C infection in COVID-19 patients is
- associated with in-hospital mortality. World Journal of Clinical Cases. 2021 Oct
- 360 10;9(29):8749.
- 11. CGHE (2022). National Hepatitis Elimination Profile for Pakistan: Key Takeaways,
- National Hepatitis Elimination Profile for Pakistan: Key Takeaways | Coalition for
- Global Hepatitis Elimination. The Coalition for Global Hepatitis Elimination (CGHE).
- Available at: https://www.globalhep.org/news/national-hepatitis-elimination-profile-
- pakistan-key-takeaways (Accessed: October 28, 2022).
- 12. Kazmi SA, Rauf A, Shafique F, Asim N, Hassan MU. Kashmiri refugees at the verge of
- hepatitis B and C epidemic in the State of Azad Jammu and Kashmir, Pakistan. Revista
- 368 de Saúde Pública. 2022 May 6;56.
- 13. WHO (2022) Vaccines and immunization, World Health Organization. World Health
- Organization. Available at: https://www.who.int/health-topics/vaccines-and-
- immunization#tab=tab_1 (Accessed: October 29, 2022).
- 14. Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. Vaccines, new opportunities for a
- new society. Proceedings of the National Academy of Sciences. 2014 Aug
- 374 26;111(34):12288-93.

- 15. Bärnighausen T, Bloom DE, Cafiero-Fonseca ET, O'Brien JC. Valuing vaccination.
- Proceedings of the National Academy of Sciences. 2014 Aug 26;111(34):12313-9.
- 16. Public Health England, Cambridge University MRC Biostatistics Unit. Direct and
- indirect impact of the vaccination programme on COVID-19 infections and mortality.
- 17. Galvani A, Moghadas SM, Schneider EC. Deaths and hospitalizations averted by rapid
- 380 US vaccination rollout. The Commonwealth Fund. Issue Briefs. 2021 Jul 7.
- 18. Government of Pakistan 2022. Covid-19 health advisory platform by Ministry of
- National Health Services Regulations and Coordination (2022) COVID. Available at:
- https://covid.gov.pk/stats/pakistan (Accessed: October 28, 2022).
- 19. Hashim, A. (2021). Vaccine hesitancy in Pakistan heightens risk of COVID resurgence.
- 385 Al Jazeera.
- 20. Weibel, C. (2021) Pakistan steps up COVID-19 vaccine roll-out, UNICEF Pakistan.
- Available at: https://www.unicef.org/pakistan/stories/pakistan-steps-covid-19-vaccine-
- roll-out (Accessed: October 27, 2022).
- 21. Barello S, Nania T, Dellafiore F, Graffigna G, Caruso R. 'Vaccine hesitancy' among
- university students in Italy during the COVID-19 pandemic. European journal of
- 391 epidemiology. 2020 Aug;35(8):781-3.
- 22. Abdulsattar, B. (2021) Ipsos survey on vaccine hesitancy in Pakistan 9th March 2021.
- Ipsos. Available at: https://www.ipsos.com/en-pk/ipsos-survey-vaccine-hesitancy-
- pakistan-9th-march-2021 (Accessed: October 27, 2022).
- 23. Khan A, Afzal S, Yaqoob A, Fatima R, Haq MU, Junaid K, Nadir A. Epidemiology of
- viral hepatitis B and C in Punjab, Pakistan: a multicenter cross-sectional study, 2017-18.
- 397 F1000Research. 2019 Dec 6;8(2065):2065.
- 398 24. Mustafa ZU, Kow CS, Hasan SS. Effect of COVID-19 on viral hepatitis services in
- Pakistan. The Lancet Gastroenterology & Hepatology. 2021 Mar 1;6(3):163-4.
- 400 25. Janz NK, Becker MH. The health belief model: A decade later. Health education
- 401 quarterly. 1984 Mar;11(1):1-47.
- 26. Shafique F, Nayab H, Asim N, Akbar N, Shafi N, Manzoor S, Eeden FV, Ali S. Attitude
- and perception towards vaccination against poliomyelitis in Peshawar, Pakistan. Revista
- de Saúde Pública. 2021 Dec 8;55:104.

- 27. Tahir MJ, Saqlain M, Tariq W, Waheed S, Tan SH, Nasir SI, Ullah I, Ahmed A.
- 406 Population preferences and attitudes towards COVID-19 vaccination: a cross-sectional
- study from Pakistan. BMC public health. 2021 Dec;21(1):1-2.
- 408 https://doi.org/10.1186/s12889-021-11814-5
- 28. Palla P, Vergadis C, Sakellariou S, Androutsakos T. Autoimmune hepatitis after
- 410 COVID□19 vaccination: A rare adverse effect?. Hepatology (Baltimore, Md.). 2022
- 411 Feb;75(2):489.
- 29. Camacho-Domínguez L, Rodríguez Y, Polo F, Gutierrez JC, Zapata E, Rojas M, Anaya
- JM. COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and
- 414 review of the literature. Journal of translational autoimmunity. 2022 Jan 4:100140.
- 30. Bril F, Al Diffalha S, Dean M, Fettig DM. Autoimmune hepatitis developing after
- coronavirus disease 2019 (COVID-19) vaccine: causality or casualty?. Journal of
- 417 Hepatology. 2021 Jul 1;75(1):222-4.
- 31. Garrido, I., Lopes, S., Simões, M.S., Liberal, R., Lopes, J., Carneiro, F. and Macedo, G.,
- 419 2021. Autoimmune hepatitis after COVID-19 vaccine–more than a coincidence. Journal
- of Autoimmunity, 125, p.102741.
- 32. Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera ☐ de la Tijera F, Aloman C, Rıza
- Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM. Outcome of COVID 19 in
- patients with autoimmune hepatitis: an international multicenter study. Hepatology. 2021
- 424 Jun;73(6):2099-109.
- 33. Jain VK, Iyengar KP, Ish P. Elucidating causes of COVID-19 infection and related deaths
- 426 after vaccination. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021
- 427 Sep 1;15(5):102212.
- 428 34. Fernandez-Davila N, Taylor MG, Anvari S. Hypersensitivity Reactions to COVID-19
- 429 Vaccines—Identify High-Risk Children and Vaccinate the Rest. JAMA pediatrics. 2022
- 430 May 1.
- 35. Kissler S, Tedijanto C, Lipsitch M, Grad YH. Social distancing strategies for curbing the
- 432 COVID-19 epidemic. MedRxiv. 2020 Jan 1.
- 36. Moosa IA. The effectiveness of social distancing in containing Covid-19. Applied
- Economics. 2020 Dec 13;52(58):6292-305.

37. Hsieh CC, Lin CH, Wang WY, Pauleen DJ, Chen JV. The outcome and implications of public precautionary measures in Taiwan–Declining respiratory disease cases in the COVID-19 pandemic. International journal of environmental research and public health. 2020 Jul;17(13):4877.
38. Ayouni I, Maatoug J, Dhouib W, Zammit N, Fredj SB, Ghammam R, Ghannem H.

38. Ayouni I, Maatoug J, Dhouib W, Zammit N, Fredj SB, Ghammam R, Ghannem H. Effective public health measures to mitigate the spread of COVID-19: a systematic review. BMC public health. 2021 Dec;21(1):1-4.

442 **<u>Tables:</u>**

Table 2-show demographic data frequencies of the participants. (n = 839).

No.	Demographic variables	Number	Percentage (%)						
		(n)							
1	Age (years)								
	18-30	479	57.1						
	31-40	164	19.5						
	41-55	151	18.0						
	56->65	45	5.4						
2	Gender								
	Male	536	63.9						
	Female	303	36.1						
3	Qualification								
	Nil	79	9.4						
	Primary	50	6.0						
	Secondary	49	5.8						
	Intermediate	86	10.3						
	Graduate	329	39.2						
	Post-graduate	246	29.3						
4	Employment status								
	Unemployed or Housewives	211	25.1						
	Students	83	9.9						
	Paid-employed	289	34.4						
	Self-employed	256	30.5						
5	Monthly Income (PKR)								
	< 30,000	513	61.1						
	> 30,000	326	38.9						
6	Ethnicity								
	Pathan	405	48.3						
	Kashmiri	353	42.1						
	Punjabi	64	7.6						
	others	17	2.0						
7	Location								
	Peshawar KPK	432	51.5						
	Muzaffarabad AJK	407	48.5						

8	Hepatitis B positive
---	----------------------

a. Question Statements

444

446

447

	No	436	52.0					
	Yes	403	48.0					
9	Hepatitis C positive							
	No	403	48.0					
	Yes	436	52.0					
10	Covid-19 vaccination							
	No	298	35.5					
	Yes	541	64.5					

Table 2- Commercially available Vaccines approved by the Government of Pakistan.

Approved Vaccines	Type of vaccine
Moderna mRna 1273	RNA
Pfizer/BioNTech BNT 162b2	RNA
Consino Ad5-NCov	Non-Replicating viral Vector
Gamaleya Spuntik V	Non-Replicating viral Vector
Oxford /Astrazeneca AZD1222	Non-Replicating viral Vector

Table 3a. Assessment of patients choosing COVID-19 vaccine for protection. Table 2B. Question statements to assess Hepatitis patient for refusing COVID-19 vaccine.

Part A: Why should a hepatitis B or C positive should take Covid-19 Vaccine?	Responses (n=839)			
vacenc.	No. of participants responded "Yes"	Percentage		
I think there is no harm in taking Covid-19 vaccine.	477	72.4%		
I believe Covid-19 vaccination will be useful in protecting the Covid-19 infection	507	76.9%		
Covid-19 vaccine is available free of cost.	524	79.5%		
My healthcare professionals and doctors has recommended me	469	71.2%		
I believe that the benefits of COVID-19 vaccine are more than the risk involved	415	63.0%		
I believe that taking Covid-19 vaccine is social responsibility	435	66.0%		
There is sufficient data regarding the vaccine safety and efficacy released by the government.	374	56.8%		
Many other hepatitis B and C are taking COVID-19 Vaccine	504	76.5%		

b. Question Statements

	Responses (n=294)			
Part B: Reason to refuse COVID-19 vaccine	No. of patients responded "Yes"	Percentage		
I think that it will damage my liver more.	161	54.7 %		
I think that COVID-19 vaccine will affect my hepatitis therapy	181	61.5 %		
I think that strict SOPs can make me prevent from infection.	218	74.1 %		
I do not have enough information about the vaccine.	186	63.2 %		
I am against vaccine in general.	158	53.7 %		
Due to previous infection with COVID-19, I don't need vaccine	172	58.5 %		
People still got covid infection after getting vaccine.	169	57.5 %		
After getting first dose I developed some allergic reactions	36	12.2%		

Table 4a. Correlation between different variables of Hepatitis B and C patients with the Covid-19 vaccine approval or rejection. b. Spearman correlation between different variables and COVID-19 vaccine.

a.											
Variables	Gender	education	location	income	Occupation	Ethnicity	Hepatitis B	He patitis C	Covid vaccine	COV 2nd dose CO	V booster
Age	1 0.124	<i> </i>	0.03	0.016	-0.03	-0.004	*	_	0.033	-0.015	0.07
Gender		0.064	*	-0.095			*	_			-0.046
education			-0.137	-0.041	0.023			_	_		-0.005
location				0.058	0.009		*		*		0.094
income					0.044	_			*		0.083
Occupation						0.082	_	-0.007			0.103
Ethnicity HepatitisB							0.03	-0.03 -1	-0.064 -0.041		0.044
HepatitisC								-1	-0.041	-0.096	-0.006
Covid vaccine									0.041	① 0.394 Z	0.008
COV 2nd dose										介	0.209
b.											
Variables Spear		Spearman Correlation r					P Value (0.05)				
Age 0.033		0.033					0.340				
		-0.018					0.612				
Education 0.064		0.064	064					0.064			
Location -0.022		-0.022	22					0.522			
Income119		119	19					0.001**			
Occupation .107		107				0.002**					
Ethnicity			-0.035					0.309			
Hepatitis B		0.041					0.240				

0.240

Hepatitis C

-0.041

Figures:




Figure 2a. No. of patients receiving Covid vaccines from approved pharmaceuticals. b. No. of Patients refused to get immunized.